Mesoblast may face fresh class action claim in Australia, 21 April 2021

A law firm in Australia is preparing a fresh class action claim against Mesoblast that alleges misleading or deceptive conduct to investors and breaches of continous disclosure in the way in which the biotech promoted the prospects of its main product candidate, Remestemcel-L. More